Christopher Richard Anzalone, Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 209,856 shares at $39.14 ($8.3M) on 2023-05-03, disclosed to the SEC on 2023-05-05.
Open-market sale of $8.3M ARWR by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.14 | 54,928 | $2.1M | 26.1% |
| 2 | $39.14 | 54,928 | $2.1M | 26.1% |
| 3 | $38.97 | 24,008 | $936K | 11.3% |
| 4 | $38.97 | 24,008 | $936K | 11.3% |
| 5 | $40.02 | 25,992 | $1.0M | 12.6% |
| 6 | $40.02 | 25,992 |
| $1.0M |
| 12.6% |
| Total | $39.32 avg | 209,856 | $8.3M | 100% |
| Filing → |
| ARWR | SELL | 2025-12-23 | $3.5M | — | Filing → |
| ARWR | SELL | 2025-12-19 | $10.9M | — | Filing → |
| ARWR | SELL | 2025-12-16 | $24.6M | — | Filing → |